Aspirin Following Anticoagulation Therapy Prevents Recurrent VTE

摘要

Does aspirin prevent recurrent venous thromboembolism (VTE) in patients who have completed an initial course of anticoagulation therapy? Bottom Line Although this ASPIRE study was underpowered to detect a difference in the primary outcome, when the results were combined with those of the WARFASA trial, the data show that daily low-dose aspirin prevents recurrent VTE as well as major vascular events without increasing bleeding in patients who have completed anticoagulation therapy for an initial, unprovoked VTE. (Level of Evidence = 1b)